Navigation Links
PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations
Date:6/1/2009

SOUTH PLAINFIELD, N.J., June 1 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Clare Kennedy has been appointed as Vice President of Commercial Operations. In this role, she will report to Theresa Natalicchio, Senior Vice President, Commercial, and will be responsible for PTC's patient services and distribution functions focusing on product access and reimbursement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are delighted to welcome Clare to our management team," said Ms. Natalicchio. "Clare's extensive expertise in national healthcare customer management, contracting and distribution will be a great asset as we expand our commercial organization and prepare for the launch of ataluren."

"I am excited to join PTC," commented Ms. Kennedy. "The company has shown an exemplary advancement of its diverse pipeline and I look forward to being part of the commercial organization with a goal to bring PTC's innovative therapies to patients."

Prior to joining PTC, Ms. Kennedy spent 16 years at Pfizer, most recently as Vice President of Account Planning, overseeing national account management, customer contracting and product access in the U.S. for the company's $21 billion portfolio. Ms. Kennedy was responsible for U.S. sales in various areas including commercial health plans, pharmacy benefit management companies, long-term care, employers, and federally-funded programs. Prior to Pfizer, Ms. Kennedy started several small businesses involved in preventive health care and clinical research. She received an A.A.S. in Nursing from Long Island College Hospital, a B.S. in Health Science from St. Francis College and a M.S. in Health Management from the American University Sc
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
2. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
3. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
7. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
8. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
9. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
10. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
11. Orexigen(R) Therapeutics to Present at Upcoming Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 This ... PHA, PBS, Starch Based Plastics, Regenerated Cellulose, PCL), ... Global Trends and Forecasts to 2019”, defines and ... analysis and forecast of its global volume and ... 54 Figures spread through 178 Slides and in-depth ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in minimally ... that its Board of Directors has appointed Dr. ... and member of the Board effective immediately. In ... responsibilities within the company, including further developing the ... manufacturing and finance. , Dr. Carol joined ...
(Date:10/25/2014)... 25, 2014 Berkshire Corporation, the ... to announce the release of the ValuSeal® IonX™ ... of contamination containment in critical processing applications. , ... higher cleanroom environments, ValuSeal® IonX™ is a laser ... wiper that continues Berkshire’s innovative focus on meeting ...
(Date:10/25/2014)... and NEW YORK ... Inc. (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), ... areas, announced it has implemented a 1-for-50 reverse ... opening of trading on Friday, October 24, 2014. ... basis under new CUSIP number 72754H109 and temporary ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... 5:00 p.m. U.S. EDT , , FRAZER, Pa., ... quarterly earnings conference call covering second quarter 2009 results for 5:00 p.m. EDT on ... , , 4:10 p.m. EDT Q2 2009 ... To participate in the conference call, dial 913-312-0379, ...
... June 30 Hospira, Inc. (NYSE: HSP ... today announced agreements with MedAssets on intravenous (I.V.) solutions ... agreement for infusion devices. The five-year MedAssets agreements are ... and equipment, and July 1, 2009, for infusion devices. ...
... needs, clinical uses and funding sources , , ROCKVILLE, ... in Rockville, Md., announced today that former Secretary of the ... board of directors. , , "I am excited ... battlefield and in emergency rooms throughout the US. I am ...
Cached Biology Technology:Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors 2
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... paradox linking artificial sweeteners such as saccharin with ... on a sweet taste has guided researchers to ... taste. , Reporting in an advance ... Chemical Senses Center describe how certain artificial sweeteners, ...
... be a key to how bacteria that infect humans ... article in the January 20 issue of the journal ... found in dirt may be the key in identifying ... infect people, predicting future clinical problems, and testing new ...
... the Kuna Indians of Panama, an international team ... is, in part, responsible, for the heart-healthy benefits ... The researchers, who are from the University of ... and Harvard Medical School, hope the findings will ...
Cached Biology News:Sweet 'water taste' paradoxically predicts sweet taste inhibitors 2Researchers use dirt to stay one step ahead of antibiotic resistance 2Researchers use dirt to stay one step ahead of antibiotic resistance 3Heart-healthy compound in chocolate identified 2
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... Sensitive Bio (for heat-labile and very volatile ... to specific applications of molecular biology and ... heat-labile samples. The RC systems can be ... and a wide selection of rotors (eliminating ...
Biology Products: